Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant increase in short interest in May. As of May 29th, there was short interest totaling 1,171 shares, an increase of 114.5% from the May 14th total of 546 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 2 shares, the days-to-cover ratio is currently 585.5 days.
Basilea Pharmaceutica Price Performance
BPMUF remained flat at $60.28 during midday trading on Friday. The business has a fifty day moving average price of $67.58 and a 200-day moving average price of $67.81. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. Basilea Pharmaceutica has a 52 week low of $59.29 and a 52 week high of $74.00.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
